Section of Vascular Surgery, Pennsylvania Hospital, Philadelphia, PA, USA.
J Vasc Surg. 2013 Feb;57(2):421-6. doi: 10.1016/j.jvs.2012.05.112. Epub 2012 Oct 9.
Placement of arterial endoprostheses across the inguinal ligament is generally thought to be contraindicated for fear of device kinking, fracture, or occlusion and possible obliteration of the deep femoral artery (DFA). We present a series of selected patients who underwent insertion of polytetrafluoroethylene-covered nitinol stents (Viabahn stent grafts. W. L. Gore and Associates Inc, Flagstaff, Ariz) crossing the middle common femoral artery (CFA) on an emergency basis or who were considered high risk for open surgery.
We treated 16 patients with 17 lesions adjacent to or within the CFA with stent grafts that originated in the common iliac (two) or external iliac (15) artery and terminated in the distal CFA (12), DFA (three), or superficial femoral (two) artery. Stent grafts were placed on an elective (10) or emergency (seven) basis for arterial occlusive disease (10), bleeding (six), and aneurysmal disease (one). Comorbidities favoring endovascular treatment were high medical risk (10) previous scarring (four), morbid obesity (two), and dense arterial calcification precluding open surgical repair (one).
The DFA was deliberately sacrificed in one of the 17 cases. No patient suffered major complications after the procedure. All grafts remained patent based on duplex ultrasound imaging during follow-up (mean, 12.3 months; range, 1-58 months). Two patients required an additional endovascular intervention to treat inflow or outflow stenoses during follow-up, yielding a 2-year primary patency rate of 93.8% and assisted primary patency rate of 100%.
These results suggest that selective placement of Viabahn stent grafts across the inguinal ligament to treat arterial occlusive disease or bleeding may prove to be safe, effective, and associated with acceptable patency rates. This strategy helps avoid complicated open arterial surgery in high-risk patients with associated multiple medical risk factors or hostile scarred groins.
一般认为,跨越腹股沟韧带放置动脉内支架是禁忌的,因为担心器械扭结、断裂或闭塞,以及可能导致股深动脉(DFA)闭塞。我们介绍了一系列选择的患者,他们因紧急情况或因开放式手术风险高而接受了聚四氟乙烯覆盖的镍钛诺支架(Viabahn 支架移植物。W. L. Gore and Associates Inc,Flagstaff,Ariz)穿过股总动脉(CFA)的治疗。
我们用支架移植物治疗了 16 名患者的 17 处病变,这些病变位于或靠近 CFA,支架移植物起源于髂总动脉(2 例)或髂外动脉(15 例),并终止于 CFA 远端(12 例)、DFA(3 例)或股浅动脉(2 例)。支架移植物是在选择性(10 例)或紧急情况下(7 例)放置的,用于治疗动脉闭塞性疾病(10 例)、出血(6 例)和动脉瘤性疾病(1 例)。有利于血管内治疗的合并症有高医疗风险(10 例)、先前有瘢痕形成(4 例)、病态肥胖(2 例)和弥漫性动脉钙化,这使得无法进行开放式手术修复(1 例)。
17 例中有 1 例故意牺牲 DFA。手术后没有患者出现重大并发症。所有移植物在随访期间(平均 12.3 个月;范围 1-58 个月)根据双功能超声成像显示仍保持通畅。两名患者在随访期间需要进行额外的血管内干预来治疗流入或流出狭窄,2 年原发性通畅率为 93.8%,辅助原发性通畅率为 100%。
这些结果表明,选择性放置 Viabahn 支架移植物跨越腹股沟韧带治疗动脉闭塞性疾病或出血可能是安全、有效且具有可接受的通畅率的。这种策略有助于避免高危患者因伴发多种医疗风险因素或腹股沟区有复杂的瘢痕形成而进行复杂的开放式动脉手术。